Literature DB >> 23170272

Interleukin-2 treatment of tumor patients can expand regulatory T cells.

Marc Beyer1.   

Abstract

Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression.

Entities:  

Year:  2012        PMID： 23170272      PMCID： PMC3494638          DOI： 10.4161/onci.20639

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.

Authors:  Shuang Wei; Ilona Kryczek; Robert P Edwards; Linhua Zou; Wojciech Szeliga; Mousumi Banerjee; Marilyn Cost; Pui Cheng; Alfred Chang; Bruce Redman; Ronald B Herberman; Weiping Zou
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

3.  A peripheral circulating compartment of natural naive CD4 Tregs.

Authors:  Danila Valmori; Andrea Merlo; Naira E Souleimanian; Charles S Hesdorffer; Maha Ayyoub
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 4.  Regulatory T cells: mechanisms of differentiation and function.

Authors:  Steven Z Josefowicz; Li-Fan Lu; Alexander Y Rudensky
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

5.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.

Authors:  Hua Zhang; Kevin S Chua; Martin Guimond; Veena Kapoor; Margaret V Brown; Thomas A Fleisher; Lauren M Long; Donna Bernstein; Brenna J Hill; Daniel C Douek; Jay A Berzofsky; Charles S Carter; E J Read; Lee J Helman; Crystal L Mackall
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

Review 6.  Regulatory T cells: major players in the tumor microenvironment.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 7.  The biology of interleukin-2.

Authors:  Thomas R Malek
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

8.  Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

Authors:  Jeffrey A Sosman; Carole Carrillo; Walter J Urba; Lawrence Flaherty; Michael B Atkins; Joseph I Clark; Janet Dutcher; Kim A Margolin; James Mier; Jarod Gollob; John M Kirkwood; David J Panka; Nancy A Crosby; Kevin O'Boyle; Bonnie LaFleur; Marc S Ernstoff
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

9.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

Authors:  Makoto Miyara; Yumiko Yoshioka; Akihiko Kitoh; Tomoko Shima; Kajsa Wing; Akira Niwa; Christophe Parizot; Cécile Taflin; Toshio Heike; Dominique Valeyre; Alexis Mathian; Tatsutoshi Nakahata; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono; Zahir Amoura; Guy Gorochov; Shimon Sakaguchi
Journal:  Immunity       Date:  2009-05-21       Impact factor: 31.745

10.  In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration.

Authors:  Marc Beyer; Beatrix Schumak; Martin R Weihrauch; Bettina Andres; Thomas Giese; Elmar Endl; Percy A Knolle; Sabine Classen; Andreas Limmer; Joachim L Schultze
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240
  10 in total
  7 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

2.  Effect of interleukin-2 treatment combined with magnetic fluid hyperthermia on Lewis lung cancer-bearing mice.

Authors:  Runlei Hu; Shenglin Ma; Xianfu Ke; Hong Jiang; Dongshan Wei; Wei Wang
Journal:  Biomed Rep       Date:  2015-11-05

3.  Nicotine exhausts CD8+ T cells against tumor cells through increasing miR-629-5p to repress IL2RB-mediated granzyme B expression.

Authors:  Chun-Chia Cheng; Hsin-Chi Lin; Ya-Wen Chiang; Jungshan Chang; Zong-Lin Sie; Bi-Ling Yang; Ken-Hong Lim; Cheng-Liang Peng; Ai-Sheng Ho; Yi-Fang Chang
Journal:  Cancer Immunol Immunother       Date:  2020-11-03       Impact factor: 6.968

Review 4.  Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.

Authors:  Ju-Ha Kim; Jisung Hwang; Ji Hoon Jung; Hyo-Jung Lee; Dae Young Lee; Sung-Hoon Kim
Journal:  Mol Cancer       Date:  2019-12-09       Impact factor: 27.401

5.  Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

Authors:  David Rafei-Shamsabadi; Saskia Lehr; Max Behrens; Frank Meiss
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

6.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

Review 7.  Trial Watch:: Oncolytic viruses for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Philippe Erbs; Jean-Marc Limacher; Xavier Preville; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-01       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.